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Abstract
Objective: Increasing the availability and accessibility of evidence-based treatments
for eating disorders is an important goal. This study investigated the effectiveness
and cost-effectiveness of guided self-help via face-to-face meetings (fGSH) and a
more scalable method, providing support via email (eGSH).
Method: A pragmatic, randomized controlled trial was conducted at three sites.
Adults with binge-eating disorders were randomized to fGSH, eGSH, or a waiting list
condition, each lasting 12 weeks. The primary outcome variable for clinical effective-
ness was overall severity of eating psychopathology and, for cost-effectiveness,
binge-free days, with explorative analyses using symptom abstinence. Costs were
estimated from both a partial societal and healthcare provider perspective.
Results: Sixty participants were included in each condition. Both forms of GSH were
superior to the control condition in reducing eating psychopathology (IRR = 1.32
[95% CI 1.77, 0.87], p < .0001; IRR = 1.62 [95% CI 2.25, 1.00], p < .0001)
and binge eating. Attrition was higher in eGSH. Probabilities that fGSH and eGSH
were cost-effective compared with WL were 93% (99%) and 51% (79%), respectively,
for a willingness to pay of £100 (£150) per additional binge-free day.
Discussion: Both forms of GSH were associated with clinical improvement and were
likely to be cost-effective compared with a waiting list condition. Provision of sup-
port via email is likely to be more convenient for many patients although the risk of
non-completion is greater.
K E YWORD S
binge eating, cognitive behavior therapy, cost-effectiveness, guided self-help
1 | INTRODUCTION
Eating disorders (EDs) are associated with significant disease burden
and healthcare costs (Simon, Schmidt, & Pilling, 2005), with a lifetime
prevalence of 8.4% in women and 2.2% in men (Galmiche, Déchelotte,
Lambert, & Tavolacci, 2019). The costs of EDs in the United States
have been estimated at around $65 billion in 2018–2019, equating to
$11,808 for each of the 5.48 million individuals who develop an ED
(Deloitte Access Economics, 2020). As an individual symptom seen
across EDs, binge eating is common and associated with significant
Received: 21 November 2020 Revised: 26 April 2021 Accepted: 10 May 2021
DOI: 10.1002/eat.23554
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. International Journal of Eating Disorders published by Wiley Periodicals LLC.
Int J Eat Disord. 2021;1–14. wileyonlinelibrary.com/journal/eat 1
morbidity (Reichborn-Kjennerud, Bulik, Sullivan, Tambs, &
Harris, 2004) although access to evidence-based treatment remains
limited (Kazdin, Fitzsimmons-Craft, & Wilfley, 2017). Effective treat-
ments are needed which can be delivered on a large scale to reduce
the burden and associated costs.
Cognitive behavior therapy (CBT) is a leading treatment for binge
eating in adults who are not underweight and there is a “guided self-
help” form of this treatment (GSH) that is briefer and can be used
both in non-specialist settings (Wilson & Zandberg, 2012; e.g., see
Carter & Fairburn, 1998) and as part of a “stepped care” model
(Mitchell et al., 2011; NICE, 2017). Recent clinical guidelines have rec-
ommended GSH as the first-line treatment for non-underweight EDs
characterized by recurrent binge eating, namely binge-eating disorder
(BED) and bulimia nervosa (BN) (Beintner, Jacobi, & Schmidt, 2014;
Hay et al., 2014; NICE, 2017). When implemented well, GSH has dem-
onstrated “clear evidence” of superiority compared with waiting list
or no-treatment control conditions (Yim & Schmidt, 2019, p. 234) and
has been shown to be cost-effective (NICE, 2017; see also Le, Hay, &
Mihalopoulos, 2018). Traditionally, the “guidance” in GSH involves
short face-to-face sessions with a trained practitioner, referred to
here as a facilitator (Carter & Fairburn, 1998), and requires the patient
to attend a clinic.
GSH can be adapted to make it more scalable, or for when face-
to-face treatment might be impossible. This has become a particularly
salient issue of late (see Waller et al., 2020), with digital treatments
becoming more prominent following the COVID-19 pandemic. Provid-
ing support via email may be more convenient for patients and
cheaper to provide than conventional face-to-face treatment,
although barriers to implementation include both patient and clinician
acceptance. In a proof-of-concept study, Ljotsson et al. (2007)
showed that providing guidance via email was acceptable and associ-
ated with large reductions in ED behaviors compared to a control con-
dition. Digital delivery of treatment based on GSH principles has also
shown promise on a larger scale, demonstrating significant reductions
in ED psychopathology that were comparable to other digital inter-
ventions (Fitzsimmons-Craft et al., 2020), suggesting that significant
gains can be made by participants in email-assisted GSH (see also
Beintner et al., 2014).
Despite the promise of GSH for the treatment of binge eating,
limited data exist regarding the cost-effectiveness of ED interventions
(Le et al., 2018). Methods for estimating cost-effectiveness have var-
ied and methodological problems are common, with interventions
often focused on single disorders, such as BED and BN
(Le et al., 2018). Looking at a broader sample of adults with regular
binge eating, Lynch et al. (2010) conducted a secondary cost-
effectiveness analysis from a randomized controlled trial and found
that the addition of GSH to treatment-as-usual (TAU) resulted in
incremental cost savings of $20.23 per binge-fee day (relative to TAU
alone). The authors concluded that GSH “is likely to be at least as
cost-effective as many accepted depression treatments” (p. 329).
Using binge-free days as a cost-effectiveness outcome represents a
useful approach to assess value-for-money of new treatments when
preference-based measures of outcomes are not available, whilst
complementing cost-utility results, whenever preference-based out-
come measures are available (König et al., 2018). Furthermore, binge-
free days reflect one of the key symptoms of interest in studies of
recurrent binge eating and “transdiagnostic” samples (Lynch
et al., 2010).
No studies have yet provided data on the cost-effectiveness of
email-facilitated GSH for binge eating and there have been no esti-
mates of its effects compared to conventional face-to-face GSH,
which is necessary to evaluate moves from more “traditional” modes
of treatment delivery to those which can be conducted online, for
example. Inclusion of a control condition in addition to “active” treat-
ments permits comparison to both the “natural course” of symptoms
(Mohr et al., 2009, p. 276) and previous work (Ljotsson et al., 2007).
In the current study, outcomes from face-to-face GSH and email-
delivered GSH were compared to those of a Waiting List control condi-
tion to examine whether these treatments are effective in naturalistic
environments and, further, to investigate the differential effects of
these interventions on several outcomes, including drop-out, symptom
outcomes, and cost-effectiveness. As a secondary analysis (stated as an
aim in the protocol; Jenkins, Luck, Burrows, & Boughton, 2014), the rel-
ative effectiveness of the two GSH treatments was explored.
2 | METHOD
2.1 | Study design and participants
This study was a pragmatic, parallel, three-arm randomized controlled
trial, delivered in a routine clinical setting to provide a balance
between internal and external validity. The study protocol has been
published (Jenkins et al., 2014). Three conditions were evaluated in
the treatment of recurrent, broadly-defined binge eating
(i.e., subjective and objective episodes): face-to-face GSH (fGSH);
email-based GSH (eGSH); and a waiting list comparison condition
(WL). All three conditions lasted 12 weeks, with assessments at pre-
treatment and post-treatment.
Participants were recruited from consecutive referrals to National
Health Service (NHS) ED centers serving a large population in central
England. Following assessment with their local service, those eligible
for the study were approached soon after by NHS clinicians and
invited to participate in the trial. Three NHS sites were used but one
was discontinued after 13 months due to inadequate recruitment. The
study protocol was approved by the South Central—Oxford B
Research Ethics Committee (13/SC/0217) and the trial was registered
with ClinicalTrials.gov (NCT01832792).
Patients were eligible for inclusion in the study if they were aged
over 17.5 years, and on clinical assessment had an ED characterized
by recurrent objective or subjective binge eating. Exclusion criteria
were recent rapid weight loss, being underweight (BMI <18.5 kg/m2),
and current and excessive substance misuse. Those who consented
were randomly allocated to one of three conditions.
To begin treatment, patients allocated to either form of GSH met
with a facilitator shortly after randomization. Outcome measures were
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completed at the start and end of the 12 weeks in all three conditions.
Data were held securely: personal identifiers were removed and
password-protected randomization details held separately.
2.2 | Randomization and masking
Participants were randomly assigned (1:1:1) to fGSH, eGSH, or
WL. To maximize recruitment and efficiency of the trial
(Kahan, 2016), participants allocated to the WL condition were
offered randomization to one of the two treatment conditions after
the 12 weeks had elapsed (see Jenkins et al., 2014). Sixty-six partici-
pants entered active treatment immediately following initial random-
ization, and 54 were re-randomized having completed a waiting
period (thus participating in both the WL condition and one inter-
vention). Simple randomization was carried out on an individual basis
using a computer-generated code set out in advance (Jenkins
et al., 2014). Participants and investigators were not blind to treat-
ment assignment due to the nature of the interventions, although
steps were taken to conceal allocation until the latest possible stage.
Data analysis was carried out according to the specified protocol by
a statistician (CR) blind to treatment condition throughout the
analyses.
2.3 | Interventions
The two GSH conditions involved participants following the cognitive
behavioral self-help program Overcoming Binge Eating (Fairburn,
2013). Each participant received a printed copy of the programme in
the initial face-to-face meeting with their facilitator. Participants in
the fGSH condition then received up to 9 further face-to-face ses-
sions (i.e., 10 in total), each lasting 20–25 min and occurring weekly at
first. Those in the eGSH condition were asked to email their facilitator
at least once a week (in lieu of attending in person) regarding their
progress following the programme and then received written asyn-
chronous feedback up to twice a week (Ljotsson et al., 2007). The role
of facilitators in the eGSH condition was similar to that in fGSH,
including provision of support and encouragement, instilling hope, and
maintaining a focus on changing eating behavior (Fairburn, 1998).
Eleven facilitators supported GSH; two were clinical psychologists
(with doctoral-level training), three were qualified nurses with mental
health experience (one of whom had advanced training in CBT), and
the remainder were “paraprofessionals” (i.e., individuals with no spe-
cific professional background and no formal CBT-specific training).
The mean number of patients allocated to each facilitator was 10.6
although there was significant variability (range = 1–33 patients) as
not all facilitators were employed for the duration of the trial.
Nine facilitators provided both treatments and two saw patients
within eGSH only. The facilitators were provided with training by the
first author, supplemented with a written manual detailing their role
(Fairburn, 1998). In addition to face-to-face briefings on the nature of
the treatment, facilitators received weekly individual supervision from
PEJ, during which they discussed the content of their sessions and
their adherence to the manual.
2.4 | Assessment of clinical outcomes
The Eating Disorder Examination Questionnaire (EDE-Q; Fairburn &
Beglin, 2008) assesses ED features over the past 28 days. Twenty-
two items can be combined to create a Global score, which provides
an index of overall ED severity (Friborg, Reas, Rosenvinge, &
Rø, 2013). In addition, self-reported frequencies of ED behaviors
(objective binge eating [OBE], self-induced vomiting, laxative use) are
generated. Cronbach's α for the Global score at baseline was 0.89.
The sample size calculation described in the protocol paper was based
on change in Global EDE-Q score. Objective binge eating was
included as a secondary outcome, in addition to self-induced vomiting
and laxative use (Linardon & Wade, 2018).
The Clinical Impairment Assessment (CIA; Bohn & Fairburn, 2008)
assesses psychosocial impairment secondary to ED features, asking
participants to rate the extent to which eating habits have affected
several life domains, such as concentration and social relationships.
Sixteen items are scored from 0 to 3, with higher scores indicating
greater impairment. Cronbach's α was 0.91.
The 34-item Clinical Outcomes in Routine Evaluation-Outcome
Measure (CORE-OM; Barkham et al., 2001) was designed for use in
evaluating the effectiveness of psychological therapies and included
as a measure of psychological distress. The measure assesses symp-
toms experienced over the previous week and items are scored from
0–4. The Total score is calculated as a mean of all items, multiplied by
ten. Cronbach's α was 0.94.
The Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1989) is a
10-item measure, where higher scores indicate better self-esteem.
Cronbach's α was 0.84.
Where items from questionnaires were missing, pro-rating
(substituting a missing item with a mean of the scale [CIA, RSES] or
subscale [CORE-OM]) was used at the data input stage. Treatment
completion was also recorded, using attendance at all planned fGSH
sessions as indicative of completion. The number of email contacts
was recorded for those in the eGSH condition.
2.5 | Economic outcomes
Binge-free days were derived from the EDE-Q and used as a primary
outcome, with additional explorative analyses using abstinence as an
outcome. Information on resource use was collected retrospectively
at the end of the treatment (with reference to the previous 3 months)
using a questionnaire designed for the current study (for details, see
Jenkins et al., 2014). In the base case analysis, resource use and costs
were estimated from a partial societal perspective, which included
(NHS) healthcare use and costs, patients' opportunity costs (e.g., cost
of attendance time), patients' travel time and costs, as well as wider
societal costs (i.e., productivity losses operationalized as absenteeism
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and presenteeism), whenever applicable. The societal perspective did
not include carers'/partners' cost, hence we use the term “partial”.
Presenteeism, defined as days of reduced productivity, was captured
in our questionnaire by participant report. Valuation of presenteeism
(i.e., cost), was based on the findings of a sample of individuals with
BED (Pawaskar et al., 2017) who reported around 30% of time lost
due to impaired productivity. Thus, if a participant in our study
reported 10 days of reduced productivity, this was “costed” as the
equivalent of 3 days of lost work, using the Human Capital Method.
This involved taking the number of days missed in the last 3 months
and multiplying this by the equivalent mean wage (£16.65 per hour;
£124.88 per day [USD: $23.35 and $175.14, respectively]). The wage
estimate was based on that of a female in her late 20s (ONS, 2017)
given the median age and gender distribution of this sample. Those
who were unemployed or retired were recorded as zero. In secondary
analyses, a healthcare provider (NHS) perspective was adopted,
including only NHS resource use and costs. No individuals were
admitted as inpatients in the 3 months prior to study entry.
2.6 | Sample size
A power calculation based on Global EDE-Q change indicated that
17 individuals per group were required to detect a large-sized effect
(with the contingency of wide confidence intervals around prior esti-
mates of effect size; Jenkins et al., 2014). The trial was terminated in
advance of the planned completion date as recruitment targets were
met more quickly than anticipated.
2.7 | Statistical analysis
The primary analysis was by intention-to-treat (ITT) with missing data
imputed using multiple imputation by chained equations; 20 datasets
were generated for each outcome. Individual analyses on each
imputed dataset were combined (Rubin, 1987). The imputation model
contained predictors of the missing data mechanism (treatment arm,
age, weight, height, ED diagnosis) and all variables contained in the
substantive model. Imputation was performed using predictive mean
matching regression for count outcomes and truncated regression for
continuous outcomes. An available case analysis was performed as a
secondary analysis. Data for seven individuals did not contain enough
information for imputation and were excluded from subsequent analy-
sis. We therefore refer to this as a modified ITT (mITT) design in the
remainder of this paper.
Analysis was by mixed effects model to account for the potential
clustering of individual outcomes within facilitators. Treatment arm
and baseline value of the outcome were included as fixed effects with
a random effect for facilitator. Negative binomial mixed effects
regression was used to deal with overdispersion for count outcomes
(e.g., OBE frequency) and mixed effects logistic regression for binary
outcomes (e.g., treatment completion). All other outcomes were ana-
lyzed using mixed effects linear regression. The primary comparisons
were between each treatment arm and control at post-treatment in
order to investigate treatment effectiveness relative to a control and
provide effect estimates that are generalizable to existing studies. The
comparison between the two treatment arms is presented, although
this is characterized as a secondary aim given limited discussion of
non-inferiority design in the protocol. A subgroup analysis based upon
baseline diagnosis (BN, BED, other specified feeding and eating disor-
der [OSFED]) was conducted for the primary outcome by including an
interaction with treatment term to the model. Analyses were per-
formed using Stata Version 13.1. Statistical significance was assessed
at the two-tailed 5% level.
2.8 | Economic analyses
Current guidelines for conducting and reporting economic evaluations
alongside trials (Husereau et al., 2013) were followed in order to
enhance transparency and completeness of outcome reporting. A par-
tial societal perspective was adopted for the base case analysis to
assess cost-effectiveness of the treatments compared to WL. In addi-
tion, a healthcare provider perspective was reported in secondary
analyses to inform decision-making about use of eGSH in the treat-
ment of EDs. Costs were expressed in pounds sterling (£) at 2016/17
prices. Given the short time horizon of the trial, discounting was not
applied to costs or effects. Multiple imputation was conducted in line
with clinical analyses, except that number of sessions attended was
used as an additional predictor of costs. For each participant, all com-
ponents of costs, stratified by category of resource use
(e.g., treatment, other healthcare resources, absenteeism,
presenteeism) were calculated by multiplying units of resource use by
their unit cost (see Table S1). Incremental cost-effectiveness ratios
were estimated and reported. Uncertainty in the cost-effectiveness
results was analyzed using cost-effectiveness acceptability curves
(CEACs), derived using Fieller's theorem (Chaudhary & Stearns, 1996;
Gray, Clarke, Wolstenholme, & Wordsworth, 2011; Polsky, Glick,
Willke, & Schulman, 1997; Willan & O'Brien, 1996) over a range of
potential threshold values (Fenwick, Marshall, Levy, & Nichol, 2006)
that the NHS and wider society might be willing to pay for an addi-
tional binge-free day or per abstinent patient (see also Le et al., 2018).
2.9 | Data sharing
We did not seek consent to share data in an online repository.
3 | RESULTS
3.1 | Participant flow and recruitment
Recruitment ran from August 1, 2013 until June 1, 2016. All individ-
uals eligible to receive GSH (N = 168) were invited to participate in
the trial. One quarter declined and were offered TAU outside the trial.
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The CONSORT flow diagram (Figure 1) shows the flow of participants
through the study, including the subgroup (n = 54) who were allo-
cated to treatment following a waiting period. Table 1 shows the
demographic characteristics of the participants in the three study con-
ditions (see also Table S2).
3.2 | Treatment completion
The odds of completing fGSH (41/60 = 68.3%) were 3.73 times
higher than those of completing eGSH (22/60 = 36.7%) (95% CIs:
1.75–7.94). The distribution of the reasons given for non-completion
F IGURE 1 Participant flow through trial [Color figure can be viewed at wileyonlinelibrary.com]
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did not differ between the two forms of GSH (see Table S3). Mean
(SD) number of contacts was 7.60 (3.40) in the fGSH condition and
8.98 (7.46) in the eGSH condition.
3.3 | Primary and secondary outcomes
3.3.1 | Primary outcome
At the end of the 12 weeks, improvements were seen on the Global
EDE-Q in both fGSH (mean difference = 1.32 [95% CIs: 1.77, 0.87],
p < .0001) and eGSH (1.62 [2.25, 1.00], p < .0001) compared to WL.
3.3.2 | Secondary outcomes
Objective binge eating was reported in 173 cases at pre-treatment,
and this subset was used to calculate cessation from binge eating
(i.e., mITT). At the end of the 12 weeks, nine fGSH patients (16.1% of
56) had ceased binge eating compared with 10 (17.9% of 56) in the
eGSH condition and one (1.9% of 54) in the Waiting List condition. As
shown in Table 2, frequency of OBEs at post-treatment was signifi-
cantly lower in the two GSH conditions than in the waiting list condi-
tion (effects were smaller in mITT analyses compared to available case
analyses; see Table 3). Improvements were also seen in CIA total
(fGSH = 9.91, CIs: 13.73, 6.09; eGSH = 10.99, CIs: 15.75,
6.23), CORE-OM total (fGSH: 5.26, CIs: 7.45, 3.06; eGSH:
5.94, CIs: 8.17, 3.70), and RSES total (fGSH: 4.36, CIs: 2.70,
6.02; eGSH: 4.59, CIs: 2.52, 6.67) (all ps < .0001). Frequency of self-
induced vomiting was significantly reduced in the fGSH condition
compared to WL (mean difference = 0.49 [0.27, 0.87], p = .0154);
there was no difference between eGSH and WL in the mITT sample
(0.60 [0.29, 1.25], p = .1720), although a difference was present in
the available case analysis (0.48 [0.24, 0.96], p < .05). A small propor-
tion of individuals reported laxative use at the start of treatment
(n = 43; 25.2% of 171 who provided data); formal statistical compari-
sons were not conducted due to compromised statistical power.
3.4 | Comparison of email versus face-to-face
No statistically significant differences were seen between the two
active treatments (fGSH, eGSH) on any of the primary or secondary
outcome variables.
3.5 | Diagnostic differences
The effect of treatment on Global EDE-Q scores did not differ by
baseline diagnosis (all ps > .88).
TABLE 1 Baseline demographic and clinical characteristics
Participant characteristics Waiting list (n = 60) Face-to-face (n = 60) Email (n = 60) Total (n = 180)
Age, y: Mean (SD) 31.2 (11.1) 30.6 (10.8) 29.6 (10.0) 30.5 (10.6)
Gender
Female 55 (91.7%) 57 (95.0%) 55 (91.7%) 167 (92.8%)
Male 5 (8.3%) 3 (5.0%) 5 (8.3%) 13 (7.2%)
Ethnic origin
White—British 48 (80.0%) 50 (83.3%) 49 (81.7%) 147 (81.7%)
Other ethnicity 12 (20.0%) 10 (16.7%) 11 (18.3%) 33 (18.3%)
Employment status
Employed 41 (68.3%) 40 (66.7%) 36 (60.0%) 117 (65.0%)
Unemployed 2 (3.3%) 2 (3.3%) 5 (8.3%) 9 (5.0%)
Full-time student 14 (23.3%) 16 (26.7%) 17 (28.3%) 47 (26.1%)
Other 3 (5.0%) 2 (3.3%) 2 (3.3%) 7 (3.9%)
Body mass index, kg/m2a 28.1 (9.8) 27.4 (8.6) 27.9 (9.4) 27.8 (9.3)
ED diagnosis
BN 34 (56.7%) 37 (61.7%) 36 (60.0%) 107 (59.4%)
BED 13 (21.7%) 13 (21.7%) 13 (21.7%) 39 (21.7%)
OSFED 13 (21.7%) 10 (16.7%) 11 (18.3%) 34 (18.9%)
Duration of ED, y: Mean (SD)b 12.3 (10.4) 12.0 (11.0) 10.7 (8.8) 11.7 (10.0)
Currently taking psychotropic medication 15 (25.0%) 18 (30.0%) 15 (25.0%) 48 (26.6%)
Note: DSM-5 criteria (APA, 2013) were used for making diagnoses. Data were not available for all participants.
Abbreviations: BN, bulimia nervosa; BED, binge-eating disorder; OSFED, other specified feeding and eating disorders.
aNs are 59, 57, 57 for WL, fGSH, and eGSH, respectively.
bNs are 53, 55, 53 for WL, fGSH, and eGSH, respectively.
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3.6 | Adverse events
Four adverse events occurred (Table S4). One concerned an eGSH
patient who was unable to contact her facilitator consistently due to the
intermittent blocking of her emails. The patient felt that this affected
her motivation to continue in treatment. The other adverse events con-
cerned deterioration in three participants' mental health, each deemed
unrelated to treatment, and so these patients remained in the study.
3.7 | Economic analysis
Estimated mean binge-free days at post-treatment were 15.27 (WL),
22.21 (fGSH), and 20.46 (eGSH). Mean (SE) societal costs over
3 months of the intervention were £1,285 (133.96) for fGSH, £1,476
(159.32) for eGSH, and £964 (139.86) for WL (Table S5; base case),
equating to £46.11 (fGSH) and £98.46 (eGSH) per additional binge-
free day compared to WL (Table 4). Further, the cost to society per
abstinent patient was estimated at £1,744.74 (fGSH) and £1,608.83
(eGSH); see Table 5. Differences in the societal perspective between
the two active interventions were largely accounted for by higher
rates of presenteeism in the eGSH condition. Taking sampling uncer-
tainty into consideration, the CEACs for the two primary base-case
analyses showed that, in view of the joint distribution of incremental
mean costs and effects, the probabilities that fGSH and eGSH were
cost-effective compared with WL were 93% (99%) (Table 4 and
Figure S1) and 51% (79%) (Table 4 and Figure S2), respectively, for a
willingness to pay of £100 (£150) per additional binge-free day.
Corresponding results for the additional explorative analyses are
reported in Table 5 and Figures S5 and S6.






Treatment comparisons mean difference
(95% CI) unless stated p-value
Mean (SE) Mean (SE)
EDE-Q global (range 0–6) Waiting list
(n = 58)





4.11 (0.15) 2.47 (0.20) Email versus waiting list 1.62 (2.25, 1.00) <.0001
Email (n = 57) 4.16 (0.15) 2.19 (0.28) Email versus face-to-face 0.29 (0.97, 0.38) .3870
OBEsa Waiting list
(n = 58)
18.0 (1.86) 14.6 (1.75) Face-to-face versus waiting list 0.48 (0.34, 0.67) <.0001
Face-to-face
(n = 58)
17.1 (1.58) 6.4 (1.26) Email versus waiting list 0.38 (0.25, 0.57) <.0001
Email (n = 51) 16.3 (1.66) 5.9 (1.39) Email versus face-to-face 0.82 (0.51, 1.30) .3901
Self-induced vomitinga Waiting list
(n = 58)
9.1 (1.99) 9.6 (1.84) Face-to-face versus waiting list 0.49 (0.27, 0.87) .0154
Face-to-face
(n = 58)
11.3 (1.99) 4.0 (1.37) Email versus waiting list 0.60 (0.29, 1.25) .1720
Email (n = 51) 9.3 (1.88) 5.6 (2.15) Email versus face-to-face 1.48 (0.65, 3.36) .3446
CIA total (range 0–48) Waiting list
(n = 58)





29.83 (1.32) 17.45 (1.68) Email versus waiting list 10.99 (15.75, 6.23) <.0001










16.99 (0.85) 10.49 (0.91) Email versus waiting list 5.94 (8.17, 3.70) <.0001
Email (n = 57) 16.42 (0.96) 9.42 (1.07) Email versus face-to-face 0.77 (3.10, 1.56) .5152
RSES total (range 0–30) Waiting list
(n = 58)
12.18 (0.62) 13.00 (0.71) Face-to-face versus waiting list 4.36 (2.70, 6.02) <.0001
Face-to-face
(n = 58)
11.53 (0.72) 16.87 (0.76) Email versus waiting list 4.59 (2.52, 6.67) <.0001
Email (n = 57) 12.08 (0.67) 17.43 (1.00) Email versus face-to-face 0.26 (1.88, 2.39) .8130
Note: Data are mean (standard error) and mean difference (95% CI) or incidence rate ratios.
aEstimates are incidence rate ratios.
JENKINS ET AL. 7
Similar results were seen from the healthcare provider (NHS) per-
spective (secondary analyses). Mean costs of delivering the intervention,
including other healthcare use, were £534 (fGSH) and £553 (eGSH) per
individual patient (Table S7). In line with the base case analysis, the
CEACs showed probabilities that fGSH and eGSH were cost-effective
compared with WL were 97% (>99%) and 78% (94%), respectively, for a
willingness to pay of £100 (£150) per additional binge-free day (Table 4;
Figures S3 and S4). Corresponding results for the additional explorative
analyses are reported in Table 5 and Figures S7 and S8.
4 | DISCUSSION
Guided self-help is recommended for the treatment of both BN and
BED in clinical guidelines such as those from NICE (2017). However,
the optimal means of delivering guidance is uncertain. To address this,
the current study compared two independent methods of delivery
against a waiting list condition. The findings indicated that both
methods were superior to a waiting list control condition and that
treatment completion was higher when the guidance was provided
face-to-face (Beintner et al., 2014). The findings suggest that both
methods are preferable to a waiting period, although the risk of attri-
tion from treatment is higher when guidance is provided via e-mail.
Greater drop-out in the eGSH condition reflects trends observed
in previous studies (see Linardon, Hindle, & Brennan, 2018)
questioning the acceptability of “non-traditional” methods of delivery
and asynchronous feedback in CBT (Victor, Krug, Vehoff, Lyons, &
Willutzki, 2018). Given similarities in the facilitators (most delivered
both treatments), contact time, and baseline characteristics, this find-
ing suggests that it is likely that attrition in GSH is strongly influenced
by how the support is provided (de Zwaan et al., 2017; Hildebrandt
et al., 2017; Sysko, 2017). Specifically, it suggests that eGSH may not




Treatment comparisons mean difference
(95% CI) unless stated p value
Mean (SD) Mean (SD)
EDE-Q global
(range 0–6)





4.0 (1.1) 2.3 (1.4) Email versus waiting list 1.58 (2.13, 1.02) <.0001
Email (n = 25) 4.2 (1.1) 2.3 (1.7) Email versus face-to-face 0.05 (0.73, 0.63) .8792
OBEsa Waiting list (n = 49) 17.1 (11.9) 14.4 (11.6) Face-to-face versus waiting list 0.43 (0.31, 0.61) <.0001
Face-to-face
(n = 45)
17.8 (12.5) 6.3 (8.9) Email versus waiting list 0.32 (0.19, 0.53) <.0001
Email (n = 25) 16.2 (9.1) 6.2 (10.3) Email versus face-to-face 0.73 (0.42, 1.27) .2692
Self-induced vomitinga Waiting list (n = 50) 8.5 (11.9) 9.8 (13.7) Face-to-face versus waiting list 0.26 (0.14, 0.50) <.0001
Face-to-face
(n = 44)
12.2 (16.2) 3.8 (9.7) Email versus waiting list 0.48 (0.24, 0.96) .0385
Email (n = 25) 8.7 (14.4) 6.4 (14.9) Email versus face-to-face 1.79 (0.75, 4.28) .1933





28.6 (10.4) 15.5 (11.2) Email versus waiting list 11.69 (16.3, 7.07) <.0001
Email (n = 25) 31.5 (10.6) 17.3 (14.2) Email versus face-to-face 0.45 (5.10, 6.00) .8735
CORE-OM total
(range 0–40)





17.2 (6.2) 10.2 (6.4) Email versus waiting list 5.43 (7.94, 2.92) <.0001
Email (n = 25) 16.1 (7.1) 9.7 (7.7) Email versus face-to-face 0.05 (3.02, 2.92) .9745
RSES total (range 0–
30)
Waiting list (n = 51) 12.2 (4.8) 12.9 (5.2) Face-to-face versus waiting list 4.82 (3.18, 6.47) <.0001
Face-to-face
(n = 46)
11.2 (5.4) 17.1 (5.3) Email versus waiting list 4.25 (2.05, 6.44) .0001
Email (n = 23) 11.8 (4.5) 16.8 (7.1) Email versus face-to-face 0.60 (3.17, 1.97) .6491
Note: Data are mean (SD) and mean difference (95% CI) or incidence rate ratios.
aEstimates are incidence rate ratios.
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be as acceptable as fGSH (see also Beintner et al., 2014; Linardon,
Messer, Lee, & Rosato, 2020) although either is likely to be preferable
to more limited treatment access (Watson et al., 2018). Whether this
difference is due to its asynchronous nature or the absence of face-
to-face contact is not clear. The finding highlights the need to explore
why levels of attrition differ between these treatments, and if this has
any effect on outcome in the longer-term (see Hildebrandt
et al., 2017). It is possible that participants did not open their e-mails,
although the digital nature of the treatment was made clear early
on. In the current study, three participants did not respond to e-mail
contact following their assessment and it was unclear whether this
reflected impaired access or a desire to discontinue treatment.
The fact that a greater number of patients in the eGSH group
were previously in the WL condition may have affected outcomes,
although this was not reflected in the proportions of those completing
treatment. Nonetheless, future studies should consider counter-
balancing given the association between long waiting times and clini-
cal outcomes (Carter et al., 2012) although it is possible that no such
effect is seen with shorter waiting times (Pellizzer, Waller, &
Wade, 2019). Similarly, although contact with other healthcare profes-
sionals was monitored for the economic analyses, it is possible that
such uncontrolled factors may have affected adherence.
In terms of cost-effectiveness, from a (partial) societal perspective
GSH delivered either face-to-face or via email was found to be cost-
effective compared to a waiting list, with the costs of treatment being
comparable to others studies adopting similar methodologies (Lynch
et al., 2010; see also NICE, 2017; Slade et al., 2018). Findings based
on the healthcare provider perspective were similar but costs associ-
ated with recurrent binge eating could be underestimated on this
basis, highlighting the importance of accounting for all costs borne by
society in mental health studies. For example, costs of facilitator time
and costs to patients (e.g., travel) were lower in the eGSH condition
but societal costs were higher due to limited effects of eGSH on work
presenteeism.
Although the assessment of presenteeism was rudimentary (and
its valuation based on an estimate from a previous study), the overall
cost estimate per individual is in line with a recent assessment of the
economic cost of eating disorders in the United States (Deloitte
Access Economics, 2020). The higher costs of presenteeism in the
eGSH group relative to those receiving fGSH, however, are difficult to
explain. The flexibility of digital interventions, whilst often seen as a
positive, can risk “transferal of clinical spaces into domestic spaces”
and require greater motivation on behalf of the patient (Yim &
Schmidt, 2019, p. 114). This might account for higher presenteeism
costs and also the higher drop-out rate in GSH, although the small
sample size for parts of the economic evaluation should be noted. The
importance of assessing all aspects of costs in digital interventions has
been highlighted previously, as the assumption that digital interven-
tions are always cheaper than traditional approaches does not always
hold (Fuertes-Guiro & Girabent-Farrés, 2017).





























































<.0001 5.19 1.96, 8.42 .002 £74.55 0.776 0.939
Abbreviation: SA, secondary analysis.
aBase case: costs: societal perspective.
bSA1: costs: healthcare provider (NHS) perspective.
cThe thresholds of £100 and £150 have been provided for illustrative purposes only because the maximum threshold value that the healthcare provider
and society are willing and able to pay for an additional binge-free day is unknown.
































































































































































































































































































































































































































































































































































































































































































































10 JENKINS ET AL.
The current study, which should be considered explorative given
its shortcomings, adds to the growing literature on cost-
effectiveness evaluations of ED treatments, being—to the best of
our knowledge—the first cost-effectiveness study alongside a RCT
including individuals with OSFED. However, as noted by other
authors (König et al., 2018; Le et al., 2018), the amount wider society
or healthcare providers are willing to pay for an additional binge-free
day or additional abstinent patient is unknown. One study (Lynch
et al., 2010) found that a GSH-based intervention was cost-saving
(from the societal perspective) compared to TAU, and another esti-
mated that conventional CBT was associated with an additional cost
of €63 per binge-free day compared to an online GSH program
(König et al., 2018). The current study suggests that face-to-face
GSH compared to a Waiting List costs society around £46 for an
additional binge-free day, with e-mail-supported GSH costing
around £98 per additional binge-free day, broadly comparable to
previous studies. The estimated costs to society of around £1,745
and £1,609 per abstinent patient for fGSH and eGSH, respectively,
compared to WL are smaller than the estimates of Crow et al. (2009)
who suggested $10,938.53 and $9,507.57 per abstinent patient in
face-to-face and telemedicine CBT respectively (2005 prices; see
also Watson et al., 2018). However, such differences may be due to
the fact that our study does not include follow-up data, and this is
an important limitation. Further work should expand on these pre-
liminary findings, which were based on relatively small numbers and
should be considered exploratory, perhaps considering a non-
inferiority trial with a pre-specified margin to directly compare these
treatments in terms of both clinical effectiveness and cost-effective-
ness. It is also recommended that additional measures used to esti-
mate health (e.g., preference-based outcomes) are included to
inform further cost-effectiveness and cost-utility studies, and that
the possible effect of comorbidities is afforded appropriate consider-
ation (Kessler, Ormel, Demler, & Stang, 2003).
Levels of symptom change were in line with the results of a sys-
tematic review by Linardon and Wade (2018), which noted binge eat-
ing cessation rates in CBT-based self-help treatments of around 14%.
In the present study, at post-treatment, 16.1% of individuals who
began fGSH and 17.9% of individuals in eGSH were abstinent from
binge eating. These numbers are lower than those found in studies of
CBT in naturalistic settings (with around 35% of intent-to-treat sam-
ples achieving abstinence; Linardon, Messer, & Fuller-
Tyszkiewicz, 2018) although GSH is highly likely to be cost-effective
when provided as part of a stepped care model (NICE, 2017). Another
noteworthy finding was that, unlike fGSH, eGSH was not significantly
more effective in reducing self-induced vomiting than the waiting list
condition. This result is consistent with the observation that CBT-
based self-help is less effective in reducing purging than binge eating
(Linardon & Wade, 2018).
The sample was recruited from a specialist ED service, and thus
degree of morbidity was high. The severity of psychopathology and
impairment was in line with similar samples (Jenkins, 2013), with over
90 % having a clinically significant level of psychosocial impairment at
baseline. Similarly, almost 90 % scored above the clinical cut-off for
the CORE-OM, a measure of general psychological distress. At post-
treatment, significant improvements were seen on eating psychopa-
thology following both fGSH and eGSH, with large differences
compared to the waiting list control condition.
Strengths of the study include the fact that the GSH programme
used has been extensively studied and widely translated. In addition,
the sample was recruited from NHS clinics and is likely to be repre-
sentative of patients referred to many specialist treatment centers,
especially given the inclusion of individuals with broadly-defined
binge eating. Measures with established psychometric properties
were used in the study and the analyses followed best-practice guide-
lines for randomized and health economics studies, including cost esti-
mates from both healthcare provider and societal perspectives. The
findings also add to the literature on cost-effectiveness for outpatient
treatment of EDs (Watson et al., 2018), and provide detailed informa-
tion on a variety of resource use and costs relevant to patients with
EDs, which could be used as parameters to inform future modeling
studies. Inclusion of an estimate of productivity costs was also a
strength given that these have often been overlooked in previous
studies (Le et al., 2018).
The pragmatic nature of the study also resulted in some limita-
tions. First, the waiting list control condition was included to control
threats to internal validity but should not be considered as equivalent
to no treatment and may inflate between-group effects (Mohr
et al., 2009). Second, as noted above, the time horizon for the eco-
nomic analysis did not include follow-up, and is likely to underesti-
mate the cost impact of interventions to the patient, society, and
healthcare provider. A more nuanced assessment of productivity costs
would have been desirable (see Brouwer, Koopmanschap, &
Rutten, 1998), so economic analyses are considered as mainly explor-
ative. Although the re-randomization design has been evaluated as an
efficient alternative to parallel designs, this is a relatively new idea
and recommendations regarding best practice are needed
(Kahan, 2016).
This trial is the first to compare the provision of GSH in person,
GSH via email, and a control condition. The findings indicate that both
forms of GSH were clinically effective and likely to be cost-effective
compared to a waiting list condition and thus are valuable brief inter-
ventions for the treatment of EDs.
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